Trial Profile
A Phase IV, Randomised, Observer-Blind,Comparator-Controlled, Single-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL Influenza Vaccine (Enzira) (2006/2007) in Healthy Older Adults aged >= 65 years.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 31 Jul 2017
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Afluria) (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors CSL
- 31 Jul 2017 Status changed from recruiting to discontinued.
- 14 Jun 2011 New trial record